Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabodenoson + Latanoprost FDC in POAG/OHT
NCT02829996Phase 2Completed
- Sponsor
- Inotek Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabodenoson in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Inotek Pharmaceuticals. Started Aug 2016; status: completed.
02
Drugs
trabodenoson
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02829996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829996.